With effective therapies now in place for both early prostate cancers and advanced prostate cancer.

Full results of the ‘147 research were provided for the first time today in a late-breaking plenary program at the American Urological Association 2011 Annual Achieving in Washington, D.C. With effective therapies now in place for both early prostate cancers and advanced prostate cancer, there exists a gap in the treatment plan for those individuals who are castrate-resistant but have not yet developed metastatic disease http://www.kamagra-en-france.net/ . Related StoriesStudy shows rare HER2 missense mutations do not spread breast cancer on the ownMeat-rich diet may boost kidney cancer riskCrucial transformation in single DNA base predisposes children to aggressive form of cancerThe data showed that XGEVA significantly improved median bone metastasis-free survival by 4.2 months, a risk reduction of 15 %, weighed against placebo had been reported with increased frequencies in the XGEVA treated sufferers.

Amgen is normally proud to make this new treatment option available to physicians and patients. Related StoriesDoing workout during puberty can improve bone wellness in adulthood, Spanish study confirmsNeighbourhood exposure to fast food outlets connected with lower BMD and BMC in newbornsGetting right nutrition throughout life can help drive back osteoporosis in old ageProlia’s approval is founded on a pivotal three-yr Phase 3 study involving 7,808 postmenopausal females with osteoporosis. Treatment with Prolia resulted in greater bone density, more powerful bones, and decreased risk for vertebral, hip and non-vertebral fractures measured at three years.